For further information, contact:

info@aspho.org, 847.375.4716

FDA-ASPHO Partnership Advances

PHO Drug Development and Regulatory Review Expertise

The US Food and Drug Administration (FDA) and ASPHO have partnered to cosponsor an 8-month  designed for early career pediatric hematology/oncology clinicians and researchers. This program addresses a critical gap in training by providing learners with a foundational understanding of pediatric hematology/oncology drug-development and the regulatory review process. The application deadline is Monday, December 29, 2025, 3pm CT.

The program takes place from April 2026 to January 2027 and will kick off at a half-day in-person session at the  (April 29, 2026, Minneapolis, MN) and includes approximately 20 hours of virtual learning over 8 months. Limited to twenty participants, the program is free, with cohort participants receiving 50% off ASPHO Conference registration.

Eligibility requirements include , pediatric hematology/oncology clinician or researcher role (3rd-year fellows through 10 years post-fellowship), and commitment to attend the in-person session and all virtual sessions.

For additional details, including program expectations and application requirements, visit the ASPHO website . Questions regarding the program should be directed to .

 is the professional medical society of pediatric hematology/oncology subspecialists and other healthcare professionals dedicated to promoting the optimal care of children, adolescents, and young adults with blood disorders and cancer. Founded in 1981, ASPHO serves over 2,000 members including physicians, researchers, advanced practice providers, and trainees by sponsoring educational and professional development programs, promoting discovery, advocating on behalf of its patient base and members, advancing professional practice and supporting partnerships to further its goals. Learn more about the Society: , , , .